drugset / Trial / NCT00289874

Montelukast in Pediatric Allergic Asthma (0476-336)(COMPLETED)

NCT00289874

Phase 3 Completed 421 enrolled Organon and Co
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a 3-week study to evaluate FEV1 following treatment with drugs in persistent asthma which is also active during allergy seasons in pediatric patients with seasonal aeroallergen sensitivity.

Timeline

Start
2006-03
Primary completion
2007-07
Completion
2007-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Montelukast Other / unclassified 5 mg Oral

Indications